secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0000950170-24-033145
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic discontinues PKU program; Q4 net loss $14.5M, cash $47.7M
------------------------------------------------------------------

- Discontinued Synpheny-3 pivotal study of SYNB1934 for PKU; evaluating strategic options.
- Q4 2023 revenue $2.8M (vs $0.1M prior year) from Roche collaboration.
- Q4 net loss $14.5M ($1.71 per share) vs $16.7M ($3.54 per share) prior year.
- Full year 2023 net loss $57.3M ($8.81 per share) vs $66.1M ($13.83) prior year.
- Cash and equivalents $47.7M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/0000950170-24-033145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017024033145/sybx-20240319.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-033145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer